NCT04853758View on ClinicalTrials.gov

Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.

PHASE3RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 6, 2021

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2024

Conditions
Chagas Cardiomyopathy
Interventions
DRUG

Sacubitril / Valsartan Oral Tablet [Entresto]

100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive sacubitril/valsartan for 6 months.

DRUG

Enalapril

100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive enalapril for 6 months.

Trial Locations (1)

05403000

RECRUITING

Heart Institute (Incor) University of Sao Paulo, São Paulo

All Listed Sponsors
collaborator

InCor Heart Institute

OTHER

lead

University of Sao Paulo General Hospital

OTHER

NCT04853758 - Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF. | Biotech Hunter | Biotech Hunter